EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study

Laura Giugliano iD, Elisabetta Augustoni, Antonio Pizzol, Anna Opramolla, Cristina Chiadò, Anna Zagaria, Irene Esposito, Giulia Roberto, Alice Ponte, Andrea Evangelista, Paola Quarello, Michele Pinon und 1 weitere

JPGN Reports · 2026-11 · 7 (4) · 564-571

DOI: 10.1002/jpr3.70186 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift JPGN Reports, online erschienen am 27.04.2026. Verfasst von Laura Giugliano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital Azienda Ospedaliera-Universitaria Città della Salute e della Scienza Turin Ita…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The efficacy of cystic fibrosis transmembrane conductance regulator ( CFTR )‐modulator therapies in preventing or ameliorating cystic fibrosis liver disease (CFLD) by correcting CFTR in cholangiocytes is not well‐documented. This study aimed to assess liver function during CFTR‐modulators.

Methods

Patients eligible to start Elexacaftor/Tezacaftor/Ivacaftor (July 2021–December 2022), followed‐up at the Piedmont Cystic Fibrosis reference Centre of the Città della Salute e della Scienza, Turin , Italy , were enrolled through a prospective single‐center cohort study and evaluated using hematological exams and liver stiffness measurement (LSM) before treatment and at 1, 3, 6, and 12 months thereafter. The treated group was compared to a group of untreated people with cystic fibrosis (pwCF), evaluated at baseline and after 12 months.

Results

Sixty‐nine treated pwCF, mean age 16.0 years, 51% males, were compared to 130 non‐treated pwCF, mean age 12.14 years, 49% males. Treated pwCF were classified by LSM as normal (7 kPa) ( N = 9, 13%). A significant trend in LSM reduction was observed at Month 12 in the subgroups with LSM 5–7 kPa and LSM > 7 kPa (−1.05, p = 0.016 and −1.57, p = 0.022, respectively). PwCF without fibrosis at baseline and non‐treated pwCF showed no LSM change over time. Liver enzyme levels increased at Month 12, trend mirrored in non‐treated pwCF for AST level, remaining within normal ranges.

Conclusions

During treatment, a significant LSM reduction was observed in pwCF with liver fibrosis at baseline, especially after Month 1. This rapid improvement could be multifactorial and may suggest a potential early response without significant liver toxicity.

Schlagwörter

Stichwörter der Autor:innen

elastographyliver cirrhosismucoviscidosistarget therapy

Autor:innen und Institutionen

  • Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital Azienda Ospedaliera-Universitaria Città della Salute e della Scienza Turin Italy.
  • Pediatric Pulmonology Unit, Regina Margherita Children Hospital Azienda Ospedaliera-Universitaria Cittá Della Salute e Della Scienza Turin Italy.
  • Unit of Clinical Epidemiology, Città della Salute e della Scienza di Torino Turin Italy.
  • Pediatric Onco-Hematology, Regina Margherita Children's Hospital Azienda Ospedaliera-Universitaria Città della Salute e della Scienza Turin Italy.

ORCID-Profile: Laura Giugliano

Zitieren

APA

Giugliano, L., Augustoni, E., Pizzol, A., Opramolla, A., Chiadò, C., Zagaria, A., Esposito, I., Roberto, G., Ponte, A., Evangelista, A., Quarello, P., Pinon, M., & Calvo, P. L. (2026). Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study. JPGN Reports, 7(4), 564-571. https://doi.org/10.1002/jpr3.70186

Vancouver

Giugliano L, Augustoni E, Pizzol A, Opramolla A, Chiadò C, Zagaria A, et al. Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study. JPGN Reports. 2026;7(4):564-571. doi:10.1002/jpr3.70186

BibTeX
@article{Giugliano2026,
  author = {Giugliano, Laura and Augustoni, Elisabetta and Pizzol, Antonio and Opramolla, Anna and Chiadò, Cristina and Zagaria, Anna and Esposito, Irene and Roberto, Giulia and Ponte, Alice and Evangelista, Andrea and Quarello, Paola and Pinon, Michele and Calvo, Pier Luigi},
  title = {Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study},
  journal = {JPGN Reports},
  year = {2026},
  volume = {7},
  number = {4},
  pages = {564--571},
  doi = {10.1002/jpr3.70186}
}
Kostenlos starten →